Navigant has picked up Dymedex Consulting, a US-based consultancy with a focus on the medical market. The addition boosts the firm’s analytics capabilities, allowing Navigant to better serve its life sciences clients. The Dymedex team, including founders Joseph Galatowitsch and Ross Meisner, will be integrated into Navigant’s Life Sciences practice.
Dymedex is a Minneapolis, Minnesota, based market development consulting firm founded in 2007. The firm is focused primarily on supporting medical technology companies to reach their market potential through data-driven market analysis. The firm leverages a number of techniques to support clients, including strategic market assessments, tactical geography planning, and market landscape analysis.
The addition of Dymedex to Navigant, boosts the firm’s capabilities in the medical technology and life sciences industries; through the addition, which will be integrated into the firm’s wider propositions, the firm says that it is better placed to support its clients, leveraging Dymedex tools, methodologies and expertise. The transaction, the value of which has not been disclosed, sees the Dymedex team, including its co-founders Joseph Galatowitsch, formerly at Medtronic and 3M, and Ross Meisner, a former Consultant at A.T. Kearney, join Navigant’s Life Sciences practice within its Healthcare segment.
Eduardo Schur, Managing Director and Global Life Sciences practice leader at Navigant, says, “In today’s medical device market, it is critical that companies create the conditions necessary to optimise growth, utilisation and adoption. Dymedex has a proven methodology to assist companies in accelerating the development of global markets. And while Dymedex has been successful in the medical technology field, we are excited by the opportunity to expand their methodologies into other life sciences areas such as pharmaceuticals and biotech.”
Joseph Galatowitsch, co-founder of Dymedex Consulting and Managing Director at Navigant, says, “Uncovering critical market insights and facilitating data-driven decisions is vital to the success of life science and med tech companies. The combination of Dymedex’s proprietary tools and methodologies with Navigant’s deep industry expertise and global footprint will enable our clients to fully capitalise on their opportunities.”
Last year Navigant, in a deal worth $22 million, added US-based RevenueMed to its Healthcare practice. Transactions completed this year include McKinnis Consulting Services (also a health services provider) and Goonan Performance Strategies, a firm specialised in process excellence.